400 Participants Needed

A Study to Identify Barriers to Cellular Therapies for People with Plasma Cell Disorders

Recruiting at 7 trial locations
HL
CT
Overseen ByCarlyn Tan, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Research Team

HL

Heather Landau, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

Inclusion Criteria

You are willing to give permission after learning about the study.
You have started a new treatment for RRMM in the last 12 months before joining the study.
You must be between 18 and 80 years old.
See 7 more

Treatment Details

Participant Groups
5Treatment groups
Experimental Treatment
Group I: Physician Group 3: HCT and CAR EnabledExperimental Treatment0 Interventions
These physicians can order and infuse stem cells and CAR T cells
Group II: Physician Group 2: CAR EnabledExperimental Treatment1 Intervention
These physicians can order and infuse CAR T cells but not stem cells.
Group III: Physician Group 1: Primary Myeloma TherapyExperimental Treatment1 Intervention
Physicians in this group refer for cellular therapy but do not perform the infusions.
Group IV: Participant Cohort 2Experimental Treatment5 Interventions
Relapse/refractory multiple myeloma/RRMM patients 70 years of age or greater
Group V: Participant Cohort 1Experimental Treatment5 Interventions
Relapse/refractory multiple myeloma/RRMM patients less than 70 years of age.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+